ES2084338T3 - Anticuerpos recombinantes especificos para el tnf alfa. - Google Patents

Anticuerpos recombinantes especificos para el tnf alfa.

Info

Publication number
ES2084338T3
ES2084338T3 ES92901287T ES92901287T ES2084338T3 ES 2084338 T3 ES2084338 T3 ES 2084338T3 ES 92901287 T ES92901287 T ES 92901287T ES 92901287 T ES92901287 T ES 92901287T ES 2084338 T3 ES2084338 T3 ES 2084338T3
Authority
ES
Spain
Prior art keywords
humanized
antibody molecules
diseases
human
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92901287T
Other languages
English (en)
Inventor
John Robert Adair
Diljeet Singh Athwal
John Spencer Emtage
Mark William Bodmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech R&D Ltd
Original Assignee
Celltech Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB1990/002017 external-priority patent/WO1991009967A1/en
Application filed by Celltech Therapeutics Ltd filed Critical Celltech Therapeutics Ltd
Application granted granted Critical
Publication of ES2084338T3 publication Critical patent/ES2084338T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE PROVEEN MOLECULAS DE ANTICUERPO RECOMBINANTES, EN PARTICULAR HUMANIZADAS, POR EJEMPLO QUIMERICA HUMANIZADA Y HUMANIZADAS POR CDR-INJERTO, QUE TIENEN ESPECIFICIDAD PARA EL TNFALFA HUMANO PARA USO EN DIAGNOSIS Y TERAPIA. EN PARTICULAR LAS MOLECULAS DE ANTICUERPO TIENEN LUGARES DE ENLACE ANTIGENO DERIVADOS DE ANTICUERPOS MONOCLONALES DE MURINA CB0006, CB0010, HTNF3 O 101,4. LOS ANTICUERPOS ANTI HTNFALFA IDONEOS HUMANIZADOS POR CDR-INJERTO COMPRENDEN DOMINIOS VARIABLES QUE COMPRENDEN UN CUADRO ACEPTEDOR HUMANO Y REGIONES DE ENLACE ANTIGENO DE DONANTE Y DONDE LOS CUADROS COMPRENDEN RESIDUOS DEL DONANTE EN POSICIONES ESPECIFICAS. LAS MOLECULAS DE ANTICUERPO SE PUEDEN UTILIZAR EN EL TRATAMIENTO TERAPEUTICO DE PACIENTE HUMANOS QUE SUFRAN O ESTEN EN RIESGO DE ENFERMEDADES ASOCIADAS CON NIVELES ELEVADOS INDESEABLES DE TNF, EN PARTICULAR PARA EL TRATAMIENTO DE ENFERMEDADES INMUNOREGULATORIAS E INFLAMATORIAS O DE CHOQUE SEPTICO, ENDOTOXICO O CARDIOVASCULAR.
ES92901287T 1990-12-21 1991-12-20 Anticuerpos recombinantes especificos para el tnf alfa. Expired - Lifetime ES2084338T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/GB1990/002017 WO1991009967A1 (en) 1989-12-21 1990-12-21 Humanised antibodies
GB919109645A GB9109645D0 (en) 1991-05-03 1991-05-03 Recombinant antibodies

Publications (1)

Publication Number Publication Date
ES2084338T3 true ES2084338T3 (es) 1996-05-01

Family

ID=10694434

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94201456T Expired - Lifetime ES2190434T3 (es) 1990-12-21 1991-12-20 Anticuerpos recombinantes especificos para tnf-alfa.
ES92901287T Expired - Lifetime ES2084338T3 (es) 1990-12-21 1991-12-20 Anticuerpos recombinantes especificos para el tnf alfa.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES94201456T Expired - Lifetime ES2190434T3 (es) 1990-12-21 1991-12-20 Anticuerpos recombinantes especificos para tnf-alfa.

Country Status (21)

Country Link
US (1) US20030199679A1 (es)
EP (3) EP0516785B1 (es)
JP (3) JP3145401B2 (es)
KR (1) KR100253426B1 (es)
AT (2) ATE134387T1 (es)
AU (2) AU657937B2 (es)
BR (1) BR9106232A (es)
CA (3) CA2329482C (es)
DE (4) DE4193302C2 (es)
DK (2) DK0516785T3 (es)
ES (2) ES2190434T3 (es)
FI (1) FI109800B (es)
GB (2) GB9109645D0 (es)
GR (1) GR3019066T3 (es)
HU (2) HUT62661A (es)
NL (1) NL9120013A (es)
NO (2) NO923231L (es)
NZ (2) NZ241147A (es)
OA (1) OA09666A (es)
PT (1) PT99934B (es)
WO (1) WO1992011383A1 (es)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69027121T3 (de) 1989-08-07 2001-08-30 Peptech Ltd., Dee Why Bindeligande für tumornekrosisfaktor
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
WO1994012215A1 (en) * 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with l-selectin
ES2159529T5 (es) † 1993-03-05 2011-03-09 Bayer Corporation Anticuerpos monoclonales humanos anti-tnf alfa.
DE4307508A1 (de) * 1993-03-10 1994-09-15 Knoll Ag Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche)
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
AU707440B2 (en) 1994-03-29 1999-07-08 Celltech Therapeutics Limited Antibodies against E-selectin
JP4231106B2 (ja) * 1995-01-23 2009-02-25 ゼノテック インコーポレイティッド 骨溶解および転移を改善する方法
US5641751A (en) * 1995-05-01 1997-06-24 Centocor, Inc. Tumor necrosis factor inhibitors
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US20140212413A1 (en) * 1995-12-11 2014-07-31 New York University Methods of Treating TNF-alpha-Mediated Diseases Using Chimeric TNF-alpha Antibodies
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
EP0791360A3 (en) * 1996-02-29 1997-09-24 Bayer Corporation Treatment of septic shock with anti-TNF antibodies
NZ333903A (en) 1996-07-24 2000-02-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1oxoisoindolines and method of reducing TNF-alpha levels in a mammal
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
EP2177517B1 (en) 1996-07-24 2011-10-26 Celgene Corporation Amino substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimide for reducing TNF alpha levels
EP1717248A1 (en) 1997-06-04 2006-11-02 Oxford Biomedica (UK) Limited Tumor targeted vector
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
DE19746868A1 (de) * 1997-10-23 1999-04-29 Knoll Ag Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
BR9815289A (pt) * 1997-11-14 2001-12-26 Euro Celtique Sa Imunoglobulina modificada, molécula, ácidonucleico isolado, célula contendo o mesmo, animalnão-humano recombinante, composiçãofarmacêutica, composição de vacina, processospara identificar ou medir ou detectar um antìgenode câncer, um antìgeno de um agente de doençainfecciosa, um ligante, e um receptor em umaamostra a ser testada, kits para detecção de umantìgeno de câncer, de um antìgeno de um agentede doença infecciosa, de um receptor celular paraum agente de doença infecciosa, de um ligante, e deum antìgeno de câncer, processos de diagnósticoou de exame para a presença de ou umapredisposição para desenvolvimento de um câncertipificado pela presença aumentada de umantìgeno de câncer, e para a presença de umagente de doença infecciosa, processos detratamento ou de prevenção de um câncertipificado pela presença de um antìgeno de câncer,de uma doença infecciosa tipificada pela presençade um antìgeno de agente de doença infecciosa, ede uma doença causada por um agente de doençainfecciosa que se liga em um receptor celular,processos para modulação de atividade de umprimeiro membro de um par de ligação, processo deprodução de uma imunoglobulina modificada,processo de produção de um ácido nucleicocodificador de imunoglobulina modificada, e, ácidonucleico isolado
KR100672892B1 (ko) * 1999-03-18 2007-01-23 셀진 코오퍼레이션 치환된 1-옥소- 및 1,3-디옥소이소인돌린스 및 염증성사이토킨 수치를 감소시키기 위한 약학적 조성물로서의이들의 사용
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
JP2003515323A (ja) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
JP2001299349A (ja) * 2000-04-19 2001-10-30 Suntory Ltd 新規組換え型抗体とそのｃｄｒのアミノ酸配列およびそれをコードする遺伝子
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
WO2002008217A2 (en) 2000-07-21 2002-01-31 Chugai Seiyaku Kabushiki Kaisha COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6709655B2 (en) 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
GB2378949B (en) * 2001-08-16 2005-09-07 Morten Steen Hanefeld Dziegiel Recombinant anti-plasmodium falciparum antibodies
EP1494710A4 (en) * 2002-03-26 2007-03-21 Centocor Inc DIABETES-RELEVANT IMMUNOGLOBULIN-BASED PROTEINS, COMPOSITIONS, PROCESSES AND USES
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
ATE518885T1 (de) 2002-05-28 2011-08-15 Ucb Pharma Sa Peg-positionsisomer von einem antikorper gegen tnfalpha (cdp870)
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
DE60333228D1 (de) 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
JP2007525409A (ja) * 2003-01-08 2007-09-06 アプライド モレキュラー エボリューション，インコーポレイテッド ＴＮＦ−α結合分子
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
AU2005212369B2 (en) 2004-02-10 2011-06-23 Musc Foundation For Research Development Inhibition of factor B, the alternative complement pathway and methods related thereto
TWI439284B (zh) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
ES2359567T3 (es) * 2004-12-29 2011-05-24 Yuhan Corporation Anticuerpo humanizado específico para el factor de necrosis tumoral-alfa.
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
CN102961746B (zh) 2005-05-16 2016-06-15 艾伯维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
AU2013207650B2 (en) * 2005-06-07 2016-04-21 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
AU2011265593B2 (en) * 2005-06-07 2013-08-15 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
AU2016204739C1 (en) * 2005-06-07 2017-10-19 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
NZ563580A (en) 2005-06-07 2010-09-30 Esbatech An Alcon Biomedical R Stable and soluble antibodies inhibiting TNFaplha
JP2009508970A (ja) 2005-09-21 2009-03-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 疼痛の局所造影および治療のためのシステム、組成物並びに方法
CA2634080A1 (en) * 2005-12-20 2007-06-28 Arana Therapeutics Limited Anti-inflammatory dab
CN101400703B (zh) 2006-02-01 2013-05-08 赛法隆澳大利亚控股有限公司 结构域抗体构建体
KR20140071452A (ko) 2006-04-05 2014-06-11 애브비 바이오테크놀로지 리미티드 항체 정제
EP2007426A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
CA2652733C (en) * 2006-05-25 2016-06-21 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
EP2505651A3 (en) 2006-12-10 2013-01-09 Dyadic International, Inc. Isolated fungus with reduced protease activity
WO2008098139A2 (en) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
WO2008149147A2 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
EP2217716A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIAL AGENTS
WO2009090189A1 (en) 2008-01-15 2009-07-23 Abbott Gmbh & Co.Kg Powdered protein compositions and methods of making same
US9365644B2 (en) * 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
WO2009142186A1 (ja) * 2008-05-20 2009-11-26 株式会社カネカ 細胞障害性組成物
MX345039B (es) * 2008-06-25 2017-01-16 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles que inhiben el tnfa.
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
WO2011127141A1 (en) * 2010-04-07 2011-10-13 Abbott Laboratories TNF-α BINDING PROTEINS
CN102675460B (zh) * 2011-02-28 2015-08-19 珠海市丽珠单抗生物技术有限公司 抗肿瘤坏死因子α的人源化抗体
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
JP2017501211A (ja) 2013-11-06 2017-01-12 アスチュート メディカル，インコーポレイテッド 生体試料中で改善された性能を有するｉｇｆｂｐ７のためのアッセイ
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
WO2017158084A1 (en) 2016-03-17 2017-09-21 Numab Innovation Ag ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
CN108884156B (zh) 2016-03-17 2021-10-01 努玛创新有限公司 抗TNFα抗体及其功能片段
EP3219727B1 (en) 2016-03-17 2020-12-16 Tillotts Pharma AG Anti-tnf alpha-antibodies and functional fragments thereof
JP6978427B2 (ja) 2016-03-17 2021-12-08 ヌマブ セラピューティクス アクチェンゲゼルシャフト 抗ＴＮＦα抗体とその機能性フラグメント
SMT202000706T1 (it) 2016-03-17 2021-01-05 Tillotts Pharma Ag Anticorpi anti-tnf alfa e frammenti funzionali di essi
MY194619A (en) 2016-06-02 2022-12-07 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
KR20190113858A (ko) 2017-01-30 2019-10-08 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
MA47442A (fr) 2017-02-07 2019-12-18 Janssen Biotech Inc Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
EP3409688A1 (en) 2017-05-31 2018-12-05 Tillotts Pharma Ag Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof
EP3456739A1 (en) 2017-09-19 2019-03-20 Tillotts Pharma Ag Use of anti-tnfalpha antibodies for treating wounds
EP3459529A1 (en) 2017-09-20 2019-03-27 Tillotts Pharma Ag Preparation of sustained release solid dosage forms comprising antibodies by spray drying
ES2938608T3 (es) 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
ES2938609T3 (es) 2017-09-20 2023-04-13 Tillotts Pharma Ag Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión
AU2018374634A1 (en) 2017-12-01 2020-05-28 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
US20210070854A1 (en) * 2017-12-29 2021-03-11 Board Of Regents, The University Of Texas System Antimicrobial nanobodies
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
IT201900000651A1 (it) 2019-01-16 2019-04-16 Pastore Lucio Tecnologia di trasferimento genico
JP7525499B2 (ja) 2019-01-31 2024-07-30 ヌマブ セラピューティクス アクチェンゲゼルシャフト ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
KR20230023663A (ko) 2020-05-21 2023-02-17 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법
JP7688150B2 (ja) 2020-12-09 2025-06-03 エイチケー イノ．エヌ コーポレーション 抗ＯＸ４０Ｌ抗体、抗ＯＸ４０Ｌ及び抗ＴＮＦαの二重特異性抗体、並びにこれらの用途
AU2024241638A1 (en) 2023-03-28 2025-10-09 Tillotts Pharma Ag Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tract

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
AU625613B2 (en) * 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies
GB8805792D0 (en) * 1988-03-11 1988-04-13 Celltech Ltd Medicaments
WO1990001950A1 (en) * 1988-08-19 1990-03-08 Celltech Limited Pharmaceutical products for anti-neoplastic therapy
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
GB9023783D0 (en) * 1990-11-01 1990-12-12 Celltech Ltd Pharmaceutical product
EP1097945B1 (en) * 1991-03-18 2007-07-04 New York University Monoclonal and chimeric antibody specific for human tumor necrosis factor
ES2159529T5 (es) * 1993-03-05 2011-03-09 Bayer Corporation Anticuerpos monoclonales humanos anti-tnf alfa.

Also Published As

Publication number Publication date
JP3145401B2 (ja) 2001-03-12
EP0626389A1 (en) 1994-11-30
AU7772394A (en) 1995-03-09
JP3383795B2 (ja) 2003-03-04
OA09666A (en) 1993-05-15
PT99934B (pt) 1998-08-31
US20030199679A1 (en) 2003-10-23
CA2329482A1 (en) 1992-06-22
CA2329482C (en) 2001-12-11
GB9217880D0 (en) 1992-10-28
NO923231D0 (no) 1992-08-18
ATE134387T1 (de) 1996-03-15
EP0927758A2 (en) 1999-07-07
DE4193302T1 (de) 1993-02-18
NL9120013A (nl) 1992-11-02
EP0626389B1 (en) 2002-12-04
EP0927758A3 (en) 2001-02-21
DE69133167D1 (de) 2003-01-16
GR3019066T3 (en) 1996-05-31
NO20012882L (no) 1992-10-20
CA2129554C (en) 1998-12-29
CA2129554A1 (en) 1992-06-22
HUT62661A (en) 1993-05-28
BR9106232A (pt) 1993-03-30
EP0516785A1 (en) 1992-12-09
CA2076540C (en) 2001-03-27
DE69133167T2 (de) 2003-07-24
GB2257145B (en) 1995-06-14
DE4193302C2 (de) 2000-08-24
GB9109645D0 (en) 1991-06-26
CA2076540A1 (en) 1992-06-22
HU211626A9 (en) 1995-12-28
WO1992011383A1 (en) 1992-07-09
PT99934A (pt) 1993-01-29
NO923231L (no) 1992-10-20
FI923737L (fi) 1992-08-20
DE69117284D1 (de) 1996-03-28
DE69117284T2 (de) 1996-09-05
FI109800B (fi) 2002-10-15
ES2190434T3 (es) 2003-08-01
NZ241147A (en) 1995-04-27
AU657937B2 (en) 1995-03-30
AU669083B2 (en) 1996-05-23
KR100253426B1 (ko) 2000-04-15
DK0626389T3 (da) 2003-03-31
ATE228853T1 (de) 2002-12-15
AU9108491A (en) 1992-07-22
EP0516785B1 (en) 1996-02-21
FI923737A0 (fi) 1992-08-20
JP2001114697A (ja) 2001-04-24
JPH05507418A (ja) 1993-10-28
NO20012882D0 (no) 2001-06-11
GB2257145A (en) 1993-01-06
DK0516785T3 (da) 1996-03-18
NZ260226A (en) 1995-04-27
JPH10136986A (ja) 1998-05-26
HU9202605D0 (en) 1992-10-28

Similar Documents

Publication Publication Date Title
ES2084338T3 (es) Anticuerpos recombinantes especificos para el tnf alfa.
ATE106750T1 (de) Funktionspezifische antikörper.
ATE153704T1 (de) Anti-t-zell rezeptordeterminanten zur behandlung von autoimmunkrankheiten
DK0807125T3 (da) Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis
ATE126441T1 (de) Pentigetide zur behandlung von nicht-ige- vermittelten entzündlichen erkrankungen.
ATE240395T1 (de) Antikörper gegen e-selektin
DK0600930T3 (da) Diagnose og behandling af autoimmune sygdomme
ATE214943T1 (de) Therapeutische zusammensetzungen die monoklonale antikörper enthalten gegen den menschlichen rezeptor für epidermalen wachstumsfaktor
ES2082850T3 (es) Inmunoglobulinas preparadas geneticamente.
DE69333348D1 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
DE69531290D1 (de) Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen
DE68925226D1 (de) Monoklonale Antikörper
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
ATE120372T1 (de) Antikörper für die antilymphozyten- antikörpertherapie.
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
DK0482089T3 (da) Fremgangsmåder til behandling af autoimmun uveoretnitis i mennesker
ES2061769T3 (es) Anticuerpo monoclonal y su utilizacion.
DK225689D0 (da) Anvendelse af metalloporphyriner til modvirkning af den toksiske virkning af tumorterapi
ES2038578T1 (es) Utilizacion de inmunoglobulinas g humanas, o de fragmentos fc de estas, como medicamento preparatorio para la administracion al hombre de anticuerpos monoclonales.
ATE95426T1 (de) Humanes karcinom-assoziertes antigen und an dieses antigen bindende antikoerper.
ATE180167T1 (de) Inhibition der ausscheidung von natrium durch die na-k-atpase
DK182188A (da) Humant tumorassocieret antigen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 516785

Country of ref document: ES